1-7 of 7
Mark Rolfe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

Free
Ronan Le Moigne, Blake T. Aftab, Stevan Djakovic, Eugen Dhimolea, Eduardo Valle, Megan Murnane, Emily M. King, Ferdie Soriano, Mary-Kamala Menon, Zhi Yong Wu, Stephen T. Wong, Grace J. Lee, Bing Yao, Arun P. Wiita, Christine Lam, Julie Rice, Jinhai Wang, Marta Chesi, P. Leif Bergsagel, Marianne Kraus, Christoph Driessen, Szerenke Kiss Von Soly, F. Michael Yakes, David Wustrow, Laura Shawver, Han-Jie Zhou, Thomas G. Martin, III, Jeffrey L. Wolf, Constantine S. Mitsiades, Daniel J. Anderson, Mark Rolfe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (11): 2375–2386.
https://doi.org/10.1158/1535-7163.MCT-17-0233
Published: 01 November 2017
View articletitled, The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Open the PDF for The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Abstract C188: Novel small molecule inhibitors of p97 disrupt cellular protein homeostasis and demonstrate anti-tumor activity in solid and hematological models.

Free
Stevan N. Djakovic, Daniel J. Anderson, Szerenke Kiss von Soly, Ronan Le Moigne, Julie Rice, Mark Rolfe, Ferdie Soriano, Eduardo Valle, Jinhai Wang, Steve Wong, David Wustrow, F. Michael Yakes, Bing Yao, Han-Jie Zhou
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C188.
https://doi.org/10.1158/1535-7163.TARG-13-C188
Published: 01 November 2013
View articletitled, Abstract C188: Novel small molecule inhibitors of p97 disrupt cellular protein homeostasis and demonstrate anti-tumor activity in solid and hematological models.
Journal Articles

Preclinical evaluation of MLN4924, the first small molecule inhibitor of NEDD8-activating enzyme (NAE) for the treatment of cancer

Free
Teresa Soucy, Peter Smith, Michael Milhollen, Allison Berger, Barbara Davis, Hua Yang, Anya Lublinsky, Julie Zhang, Tary Traore, Usha Narayanan, Jie Yu, James Garnsey, James Gavin, Gabriel Weatherhead, Courtney Cullis, Edward Olhava, Stepan Vyskocil, Mark Rolfe, Steven Langston
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B280.
Published: 01 November 2007
View articletitled, Preclinical evaluation of MLN4924, the first small molecule inhibitor of NEDD8-activating enzyme (NAE) for the treatment of cancer
Journal Articles

Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer

Free
Mark Rolfe, Michael Milhollen, Allison Berger, Pete Smith, Steve Langston, Teresa Soucy
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): CN06-02.
Published: 01 November 2007
View articletitled, Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer
Journal Articles

The JAMM motif of human deubiquitinase Poh1 is essential for cell viability

Free
Melissa Gallery, Jonathan L. Blank, Yinghui Lin, Juan A. Gutierrez, Jacqueline C. Pulido, David Rappoli, Sunita Badola, Mark Rolfe, Kyle J. MacBeth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (1): 262–268.
https://doi.org/10.1158/1535-7163.MCT-06-0542
Published: 19 January 2007
View articletitled, The JAMM motif of human deubiquitinase Poh1 is essential for cell viability
Open the PDF for The JAMM motif of human deubiquitinase Poh1 is essential for cell viability in another window
Journal Articles

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

Free
Mark J. Williamson, Jonathan L. Blank, Frank J. Bruzzese, Yueying Cao, J. Scott Daniels, Lawrence R. Dick, Jason Labutti, Anne M. Mazzola, Ashok D. Patil, Corinne L. Reimer, Marjorie S. Solomon, Matthew Stirling, Yuan Tian, Christopher A. Tsu, Gabriel S. Weatherhead, Julie X. Zhang, Mark Rolfe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (12): 3052–3061.
https://doi.org/10.1158/1535-7163.MCT-06-0185
Published: 15 December 2006
View articletitled, Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Open the PDF for Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib in another window
Includes: Supplementary data
Journal Articles

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

Free
Jordi Codony-Servat, Maria A. Tapia, Marta Bosch, Cristina Oliva, Josep Domingo-Domenech, Begoña Mellado, Mark Rolfe, Jeffrey S. Ross, Pere Gascon, Ana Rovira, Joan Albanell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 665–675.
https://doi.org/10.1158/1535-7163.MCT-05-0147
Published: 16 March 2006
View articletitled, Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
Open the PDF for Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells in another window